Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

Tong, Tongyu; Lei, Hanqi; Guan, Yupeng; Yang, Xiangwei; Liao, Guolong; Li, Yamei; Jiang, Donggen; Pang, Jun

doi:10.3389/fonc.2020.586192

Cited by 5 publications

(4 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The measurement of tALP considers all of those isoforms, in which bone-specific ALP (BSAP) is included ( 20 ) . Together, BSAP and nonspecific hepatic ALP account for approximately 90% of the tALP, therefore being the two most abundant isoforms ( 21 ) .…”

Section: Discussionmentioning

confidence: 99%

Behavior of total alkaline phosphatase after radium-233 therapy in metastatic castration-resistant prostate cancer: a single-center, real-world retrospective study

Lopes,

Pedras,

Ferreira

et al. 2023

Radiol Bras

View full text Add to dashboard Cite

Objective: To describe the behavior of total alkaline phosphatase (tALP) in patients with metastatic castration-resistant prostate cancer receiving radium-223 therapy, in a real-world scenario, and to describe overall survival (OS) among such patients. Materials and Methods: This was a retrospective study involving 97 patients treated between February 2017 and September 2020. Patients were stratified by the baseline tALP (normal/elevated). A tALP response was defined as a ≥ 30% reduction from baseline at week 12. For patients with elevated baseline tALP, we also evaluated treatment response as a ≥ 10% reduction in tALP after the first cycle of treatment. We defined OS as the time from the first treatment cycle to the date of death. Results: There was a significant reduction in the median tALP after each cycle of treatment (p < 0.05 for all). Data for tALP at week 12 were available for 71 of the 97 patients. Of those 71 patients, 26 (36.6%) responded. Elevated baseline tALP was observed in 47 patients, of whom 19 (40.4%) showed a response. Longer OS was observed in the patients with normal baseline tALP, in those with elevated baseline tALP that showed a response to treatment (≥ 10% reduction), and in those who received 5-6 cycles of therapy. Conclusion: The tALP may be used to predict which patients will benefit from treatment with a greater number of cycles of radium-223 therapy and will have longer OS.

show abstract

Section: Discussionmentioning

confidence: 99%

Behavior of total alkaline phosphatase after radium-233 therapy in metastatic castration-resistant prostate cancer: a single-center, real-world retrospective study

Lopes,

Pedras,

Ferreira

et al. 2023

Radiol Bras

View full text Add to dashboard Cite

show abstract

“…The PSA level is an independent prognostic factor ( 159 ). The extent of PCa-induced metastatic bone disease is indicated by the expression of alkaline phosphatase, an enzyme that is surface-expressed by osteoblasts and is frequently used to predict the prognosis and course of treatment for patients with PCa bone metastases ( 160 ). Zoledronic acid is the most commonly used drug in patients with PCa bone metastases.…”

Section: Chinese Patent Medicinementioning

confidence: 99%

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Ni,

Xue,

Wang

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

Malignant tumors are complex systemic chronic diseases and one of the major causes of human mortality. Targeted therapy, chemotherapy, immunotherapy, and radiotherapy are examples of mainstream allopathic medicine treatments that effective for intermediate and advanced malignant tumors. The ongoing use of conventional allopathic medicine has resulted in adverse responses and drug resistance, which have hampered its efficacy. As an important component of complementary and alternative medicine, Chinese medicine has been found to have antitumor effects and has played an important role in enhancing the therapeutic sensitivity of mainstream allopathic medicine, reducing the incidence of adverse events and improving immune-related functions. The combined application of adjuvant Chinese medicine and mainstream allopathic medicine has begun to gain acceptance and is gradually used in the field of antitumor therapy. Traditional natural medicines and their active ingredients, as well as Chinese patent medicines, have been proven to have excellent therapeutic efficacy and good safety in the treatment of various malignant tumors. This paper focuses on the mechanism of action and research progress of combining the above drugs with mainstream allopathic medicine to increase therapeutic sensitivity, alleviate drug resistance, reduce adverse reactions, and improve the body’s immune function. To encourage the clinical development and use of Chinese herb adjuvant therapy as well as to provide ideas and information for creating safer and more effective anticancer medication combinations, the significant functions of Chinese herb therapies as adjuvant therapies for cancer treatment are described in detail.

show abstract

“…It is anticipated it will aid in formulating regular cancer therapy and follow-up plans [38]. The degree of BM is indicated by changes in bone turnover and osteoblastic activity, which are reflected in changes in ALP levels [38][39][40]. Increased levels of ALP were seen in PCa patients with BM, and decreases in ALP levels were also observed in PCa patients with BM after radium-233 radionuclide therapy [41,42].…”

Section: Alkaline Phosphatase (Alp)mentioning

confidence: 99%

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Ying

Mao

Sheng

et al. 2023

JPM

View full text Add to dashboard Cite

Prostate cancer (PCa) causes deaths worldwide, ranking second after lung cancer. Bone metastasis (BM) frequently results from advanced PCa, affecting approximately 90% of patients, and it also often results in severe skeletal-related events. Traditional diagnostic methods for bone metastases, such as tissue biopsies and imaging, have substantial drawbacks. This article summarizes the significance of biomarkers in PCa accompanied with BM, including (1) bone formation markers like osteopontin (OPN), pro-collagen type I C-terminal pro-peptide (PICP), osteoprotegerin (OPG), pro-collagen type I N-terminal pro-peptide (PINP), alkaline phosphatase (ALP), and osteocalcin (OC); (2) bone resorption markers, including C-telopeptide of type I collagen (CTx), N-telopeptide of type I collagen (NTx), bone sialoprotein (BSP), tartrate-resistant acid phosphatase (TRACP), deoxypyridinoline (D-PYD), pyridoxine (PYD), and C-terminal pyridinoline cross-linked telopeptide of type I collagen (ICTP); (3) prostate-specific antigen (PSA); (4) neuroendocrine markers, such as chromogranin A (CgA), neuron-specific enolase (NSE), and pro-gastrin releasing peptide (ProGRP); (5) liquid biopsy markers, such as circulating tumor cells (CTCs), microRNA (miRNA), circulating tumor DNA (ctDNA), and cell-free DNA (cfDNA) and exosomes. In summary, some of these markers are already in widespread clinical use, while others still require further laboratory or clinical studies to validate their value for clinical application.

show abstract

Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial

Cited by 5 publications

References 58 publications

Behavior of total alkaline phosphatase after radium-233 therapy in metastatic castration-resistant prostate cancer: a single-center, real-world retrospective study

Behavior of total alkaline phosphatase after radium-233 therapy in metastatic castration-resistant prostate cancer: a single-center, real-world retrospective study

Integrating Chinese medicine into mainstream cancer therapies: a promising future

Biomarkers for Prostate Cancer Bone Metastasis Detection and Prediction

Contact Info

Product

Resources

About